ClinicalTrials.gg
Active, not recruitingNCT06422884Updated Feb 24, 2026

A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

A Phase 2 interventional study of ENV-101 and Placebo in Idiopathic Pulmonary Fibrosis and Progressive Fibrosing Interstitial Lung Disease, sponsored by Endeavor Biomedicines, Inc.. Active, not recruiting at 78 sites in 14 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by Endeavor Biomedicines, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
213
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies in Idiopathic Pulmonary Fibrosis with a site in France — 10 open to participants now, 16 under way, 5 of them phase 3. Idiopathic Pulmonary Fibrosis · France.

Enrollment
25th of 57
213 · median 178
Started
2024
with 6 others
Phase 2
24 of 70
4 open now
Primary completion
2026-10
later than 4 of 15 live
Registered
61st of 70
by date

Among the 70 studies in Idiopathic Pulmonary Fibrosis with a site in France, this one is the 25th largest by enrollment of the 57 interventional ones that give a count, is one of 7 that started in 2024, is one of 24 in phase 2, reaches primary completion later than 4 of the 15 other live ones, and was the 61st registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

10 of the 70 studies in Idiopathic Pulmonary Fibrosis with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Idiopathic Pulmonary Fibrosis with a site in France, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF). Another goal of this study is to better understand the safety and tolerability of ENV-101 in this patient population.

Read the detailed description

This trial is a 6-month, randomized, double-blind, controlled, dose-ranging trial of ENV-101 in adult patients with idiopathic pulmonary fibrosis (IPF). Patients are allowed to continue treatment with approved standard of care (e.g., nintedanib, pirfenidone) during the trial. Patients will be randomized to one of 3 dose levels of ENV-101 or placebo at baseline. The objectives of this trial are to characterize the efficacy, antifibrotic activity, and safety of ENV-101 to select the Phase 3 dose of ENV-101.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
  • Progressive Fibrosing Interstitial Lung Disease

Keywords

  • taladegib
  • hedgehog pathway inhibitor
  • pulmonary fibrosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥ 40 years old with an IPF diagnosis as confirmed by the Investigator.
  • Percent predicted FVC of ≥ 45% at study start.
  • Percent predicted diffusing capacity of lung for carbon monoxide (DLCO) ≥ 25%, adjusted for (Hgb) at study start.
  • Ability to perform spirometry tests.
  • Either stable treatment with standard of care (SoC) [i.e., antifibrotics, (PPF only)] for at least 3 months prior to study start or not treated with SoC for at least 8 weeks prior to study start.

Exclusion criteria

Exclusion Criteria:

  • Evidence of other known causes of interstitial lung disease (ILD).
  • (FEV1)/FVC ratio \<0.7 at study start.
  • History of , including carcinoma during the preceding 5 years from study start, with the following exceptions:

    1. Prior history of in situ melanoma, basal or squamous cell skin cancer if treated with curative therapy.
    2. Patients with prostate cancer that are managed by surveillance.
    3. Patients with ductal carcinoma in situ, treated surgically with curative intent.
  • Patients with moderate to severe hepatic impairment ( B and C).
  • Smoking (including vaping) within 6 months of study start; current smoker, or unwillingness to refrain from smoking during the clinical trial duration.
  • Active or suspected alcohol or drug abuse in the opinion of the Investigator.
  • Currently enrolled in another device or drug trial, or less than 3 months from study start since ending another investigational device or drug trial(s) or receiving other investigational treatment(s).
  • Presence of active infection at study start or confirmed active (HIV), virus (HBV) or virus (HCV).
  • Major surgery requiring hospitalization (according to the Investigator) performed within 3 months prior to study start or planned during the course of the trial. Being on a transplant list is allowed.
  • Occurrence of serious illness requiring hospitalization within 90 days prior to study start.
  • Current or previous use (within 28 days prior to study start) of the following:

    1. Endothelin receptor antagonist
    2. Riociguat
    3. Prostacyclin or prostacyclin analogue
    4. Radiation to the lungs
    5. Oral >15 mg/day
  • Use of cyclophosphamide or tocilizumab within 8 weeks, or rituximab within 6 months, prior to study start.
  • Use of drugs that are known moderate or stronger inhibitors or inducers within 14 days prior to study start. Patients must also agree not to eat fruits that inhibit CYP3A4 such as grapefruit, Seville oranges, pomelo and star fruit.
  • Patients of who are sexually active and unwilling to use for the duration of the study and for 3 months after their final dose of study drug.
  • Females that are pregnant or nursing.
  • Patients that are unwilling to refrain from blood or blood product donation for the duration of the study and for 30 days after their final dose of study drug.
  • Males who are unwilling to refrain from sperm donation and females who are unwilling to refrain from egg donation for the duration of the study and for 3 months after their final dose of study drug.
  • Patients with a history of a severe allergic reaction or anaphylactic reaction or known to any component of ENV-101.
  • Patients who have previously taken ENV-101.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
213 participants (actual)

Study arms

  • Experimental
    ENV-101 Low Dose (IPF Population)

    Drug: ENV-101

  • Experimental
    ENV-101 Mid Dose (IPF Population)

    Drug: ENV-101

  • Experimental
    ENV-101 High Dose (IPF Population)

    Drug: ENV-101

  • Placebo comparator
    Placebo (IPF Population)

    Drug: Placebo

Interventions

  • oral tablet, dosed once a day

    Also known as: taladegib

  • DrugPlacebo

    oral tablet, dosed once a day

06

What researchers measure

Primary outcomes

  1. Change in percent predicted forced vital capacity (ppFVC) compared to placebo

    ppFVC is a measure of lung function

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Absolute change in FVC (mL) compared to placebo

    FVC is a measure of lung function

    Time frame: Baseline and Week 24

  2. Time to disease progression (absolute decline in ppFVC >10%, IPF-related hospitalization, or death) compared to placebo

    Time frame: Baseline and Week 24

  3. Absolute change in the Living with Pulmonary Fibrosis Symptoms (L-PF Symptoms) Questionnaire Cough domain score compared to placebo

    The L-PF Symptoms Questionnaire Cough domain consists of 6 questions regarding a subject's experience with cough over the prior 24 hours. Questions have response options on a five-point numeric rating scale with an anchor of 0 ("Not at all") to 4 ("Extremely"). Total score for the Cough domain is normalized to the range 0 to 100, with higher scores indicating greater impairment.

    Time frame: Baseline and Week 24

  4. Absolute change in the L-PF Symptoms Questionnaire Dyspnea domain score compared to placebo

    The L-PF Symptoms Questionnaire Dyspnea domain consists of 12 questions regarding a subject's experience with dyspnea (shortness of breath) over the prior 24 hours. Questions have response options on a five-point numeric rating scale with an anchor of 0 ("Not at all") to 4 ("Extremely"). Total score for the Dyspnea domain is normalized to the range 0 to 100, with higher scores indicating greater impairment.

    Time frame: Baseline and Week 24

  5. Absolute change in the L-PF Symptoms Questionnaire Fatigue domain score compared to placebo

    The L-PF Symptoms Questionnaire Fatigue domain consists of 5 questions regarding a subject's experience with fatigue over the prior 24 hours. Questions have response options on a five-point numeric rating scale with an anchor of 0 ("Not at all") to 4 ("Extremely"). Total score for the Fatigue domain is normalized to the range 0 to 100, with higher scores indicating greater impairment.

    Time frame: Baseline and Week 24

  6. Absolute change in the L-PF Symptoms module score compared to placebo

    The L-PF Symptoms module is a 23-item patient-reported outcome measure designed to assess the severity of dyspnea (12 items), cough (6 items), and fatigue (5 items) experienced by a subject over the prior 24 hours. Questions have response options on a five-point numeric rating scale with an anchor of 0 ("Not at all") to 4 ("Extremely"). Total score for the Symptoms module is normalized to the range 0 to 100, with higher scores indicating greater impairment.

    Time frame: Baseline and Week 24

  7. Absolute change in the L-PF Impacts module score compared to placebo

    The L-PF Impacts module consists of 21 questions regarding a subject's experience with the impacts of pulmonary fibrosis on daily life over the prior week. Questions have response options on a five-point numeric rating scale with an anchor of 0 ("Not at all") to 4 ("Extremely"). Total score for the Impacts module domain is normalized to the range 0 to 100, with higher scores indicating greater impairment.

    Time frame: Baseline and Week 24

  8. Absolute change in total lung capacity (TLC) by chest high-resolution computed tomography (HRCT) imaging compared to placebo

    HRCT is a method of imaging which is more precise than chest x-ray in the diagnosis and monitoring of diseases of the lung tissue and the airways.

    Time frame: Baseline and Week 24

  9. Absolute change in % quantitative interstitial lung disease (QILD) by chest HRCT imaging compared to placebo compared to placebo

    Time frame: Baseline and Week 24

  10. Absolute change in % quantitative ground glass opacity (QGG) by chest HRCT imaging compared to placebo

    Time frame: Baseline and Week 24

  11. Absolute change in % quantitative lung fibrosis (QLF) by chest HRCT imaging compared to placebo

    Time frame: Baseline and Week 24

07

Study locations

78 sites
  • Research Site
    Quilmes, Buenos Aires B1878FNR, Argentina
  • Research Site
    Buenos Aires, 1888, Argentina
  • Research Site
    Buenos Aires, C1426ABP, Argentina
  • Research Site
    Mendoza, 5501, Argentina
  • Research Site
    Mendoza, CP 5500, Argentina
  • Research Site
    Camperdown, New South Wales 2050, Australia
  • Research Site
    Macquarie Park, New South Wales 2109, Australia
  • Research Site
    Brisbane, Queensland 4032, Australia
  • Research Site
    South Brisbane, Queensland 4101, Australia
  • Research Site
    Box Hill, Victoria 3128, Australia
  • Research Site
    Nedlands, Western Australia 6009, Australia
  • Research Site
    Graz, Styria 8036, Austria
  • Research Site
    Vienna, 1090, Austria
  • Research Site
    Dinant, Namur 5500, Belgium
  • Research Site
    Brussels, 1070, Belgium
  • Research Site
    Brussels, 1200, Belgium
  • Research Site
    Edmonton, Alberta T6G 2C8, Canada
  • Research Site
    Vancouver, British Columbia V6Z 2K5, Canada
  • Research Site
    Ajax, Ontario L1S 2J5, Canada
  • Research Site
    Montreal, Quebec H2X 0A9, Canada
  • Research Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Research Site
    Trois-Rivières, Quebec G8T 7A1, Canada
  • Research Site
    Angers, 49933, France
  • Research Site
    Bordeaux, 33604, France
  • Research Site
    Caen, 14033, France
  • Research Site
    Dijon, 21000, France
  • Research Site
    Montpellier, 34090, France
  • Research Site
    Nantes, 44093, France
  • Research Site
    Paris, 75014, France
  • Research Site
    Paris, 94270, France
  • Research Site
    Rennes, 35033, France
  • Research Site
    Tours, 37044, France
  • Research Site
    Giessen, Hesse 35398, Germany
  • Research Site
    Immenhausen, Hesse 34376, Germany
  • Research Site
    Hanover, Lower Saxony 30625, Germany
  • Research Site
    Essen, North Rhine-Westphalia 45239, Germany
  • Research Site
    Berlin, 13125, Germany
  • Research Site
    Leipzig, 4103, Germany
  • Research Site
    Dublin, Leinster D05 AT88, Ireland
  • Research Site
    Dublin, Leinster D07 A8NN, Ireland
  • Research Site
    Cork, Munster T12 DC4A, Ireland
  • Research Site
    Dublin, D04 T6F4, Ireland
  • Research Site
    Bologna, Forli-Cesena 47121, Italy
  • Research Site
    Padova, Padua 35128, Italy
  • Research Site
    Florence, Tuscany 50314, Italy
  • Research Site
    Catania, 95123, Italy
  • Research Site
    Milan, 20123, Italy
  • Research Site
    Turin, 10126, Italy
  • Research Site
    Kuala Lumpur, Selangor 42300, Malaysia
  • Research Site
    Kuala Lumpur, Selangor 50590, Malaysia
  • Research Site
    Kuala Lumpur, Selangor 56000, Malaysia
  • Research Site
    Monterrey, Nuevo León 64060, Mexico
  • Research Site
    Monterrey, Nuevo León 64718, Mexico
  • Research Site
    San Nicolás de los Garza, Nuevo León 66465, Mexico
  • Research Site
    San Juan del Río, Querétaro 76800, Mexico
  • Research Site
    Chihuahua City, 31230, Mexico
  • Research Site
    Mexico City, 14080, Mexico
  • Research Site
    Oaxaca City, 68000, Mexico
  • Research Site
    Puebla City, 72180, Mexico
  • Research Site
    Auckland, New Zealand
  • Research Site
    Christchurch, 8011, New Zealand
  • Research Site
    Hamilton, New Zealand
  • Research Site
    Seoul, (Deogyang District) 10475, South Korea
  • Research Site
    Ulsan, (Dong District) 44033, South Korea
  • Research Site
    Busan, (Haeundae District) 48108, South Korea
  • Research Site
    Seoul, (Seongbuk District) 02841, South Korea
  • Research Site
    Seoul, (Songpa District) 05505, South Korea
  • Research Site
    Seoul, (Yongsan District) 04401, South Korea
  • Research Site
    Seoul, 16499, South Korea
  • Research Site
    Belfast, BT9 7AB, United Kingdom
  • Research Site
    Birmingham, B15 2GW, United Kingdom
  • Research Site
    Birmingham, B9 5SS, United Kingdom
  • Research Site
    Cambridge, CB2 0AY, United Kingdom
  • Research Site
    Edinburgh, EH1 3EG, United Kingdom
  • Research Site
    Exeter, EX2 5DW, United Kingdom
  • Research Site
    Leicester, LE3 9QP, United Kingdom
  • Research Site
    London, SW3 6NP, United Kingdom
  • Research Site
    Londonderry, BT47 6SB, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Oct 2026, 23 months after the start.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's planned 23 months is below that.

Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2024
First posted
May 21, 2024
StartActual
Nov 15, 2024
Primary completionEst.
Oct 2026
CompletionEst.
Oct 2026
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06422884
Lead sponsor
Endeavor Biomedicines, Inc.
Responsible party
Sponsor
First posted
May 21, 2024
Start date
Nov 15, 2024
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Feb 24, 2026

Study contacts

Lisa Lancaster, M.D.
study director · Endeavor Biomedicines

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY2940680

Start the discussion